Pappagallo, Marco
Kosten, Thomas R.
Gorodetzky, Charles W.
Vocci, Frank J.
Sapienza, Frank L.
De Martin, Sara
Comai, Stefano http://orcid.org/0000-0002-5686-7194
Mattarei, Andrea
Inturrisi, Charles E.
Manfredi, Paolo L.
Funding for this research was provided by:
Relmada Therapeutics Inc.
Relmada Therapeutics, Inc.
Article History
Received: 16 January 2024
Revised: 15 May 2024
Accepted: 17 May 2024
First Online: 28 May 2024
Competing interests
: Drs. De Martin, Mattarei, and Comai are employed by or have received compensation from companies or institutions that received funding from Relmada Therapeutics, Inc. Drs. Gorodetzky, Vocci, Sapienza, Kosten, Manfredi, Pappagallo, and Inturrisi have received consultant fees from Relmada Therapeutics, Inc. Frank Vocci also is a consultant for Takeda Pharmaceuticals and on the Scientific Advisory Board of Exavir Therapeutics, Inc. Drs. De Martin, Mattarei, and Comai have received grant support from MGGM LLC and consultant fees from Neuroarbor LLC, companies affiliated with Relmada Therapeutics. The authors of this letter wish to further disclose that the determination of the antidepressant mechanism of action of esmethadone may have a direct impact on the schedule (i.e., schedule II to V) classification of esmethadone, and ultimately on its commercial prospects.